NeuroClues' technology is unique in that it can be used in a regular clinician's office without the need for a dark room or specialist computing hardware. The company is currently seeking FDA approval and hopes to gain clearance for use of its device as a clinical support tool in the US later this year, with EU approval expected in 2025. The startup recently closed a €5 million pre-Series A funding round and plans to raise a Series A in the next 12 to 18 months.
Key takeaways:
- French-Belgian medtech startup neuroClues is developing high-speed eye-tracking technology that incorporates AI-driven analysis to help diagnose neurodegenerative conditions, starting with Parkinson’s disease.
- The technology involves a proprietary, portable headset that captures eye movements at 800 frames per second, which can then be analyzed in a few seconds to provide data that can be used as disease biomarkers.
- neuroClues is in the process of filing an application for FDA approval and hopes to gain clearance for use of its device as a clinical support tool in the US later this year, with anticipated EU approval in 2025.
- The startup has recently closed a €5 million pre-Series A round of funding, led by White Fund and the European Commission’s EIC Accelerator program, and plans to raise a Series A in the next 12 to 18 months.